{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:49:18Z","timestamp":1791820158727,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Dermatologische Leitlinien stellen eine wesentliche Grundlage f\u00fcr die evidenzbasierte Diagnostik, Therapie und Pr\u00e4vention von Hauterkrankungen dar. In Deutschland werden sie ma\u00dfgeblich unter Federf\u00fchrung der Deutschen Dermatologischen Gesellschaft (DDG) in Zusammenarbeit mit dem Berufsverband der Deutschen Dermatologen (BVDD) entsprechend den methodischen Vorgaben der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) entwickelt und regelm\u00e4\u00dfig aktualisiert. In den Jahren 2025 und 2026 wurden zahlreiche neue bzw. umfassend \u00fcberarbeitete Leitlinien ver\u00f6ffentlicht, die ein breites Spektrum dermatologischer Erkrankungen abdecken. Dieses umfasst sowohl h\u00e4ufige chronisch entz\u00fcndliche Dermatosen als auch seltene Erkrankungen, infektiologische Fragestellungen, Berufsdermatosen, Autoimmundermatosen sowie rehabilitative und diagnostische Versorgungskonzepte. Ziel dieser \u00dcbersicht ist die praxisorientierte Zusammenfassung ausgew\u00e4hlter, neu publizierter oder aktualisierter deutscher Leitlinien dieses Zeitraums mit besonderer klinischer Relevanz f\u00fcr die klinische Versorgung. Ber\u00fccksichtigt wurden insbesondere Leitlinien mit wesentlichen diagnostischen oder therapeutischen Neuerungen sowie mit hoher Relevanz f\u00fcr die klinische Praxis. Da die ausgew\u00e4hlten Leitlinien unterschiedliche Entwicklungsstufen umfassen, unterscheiden sie sich hinsichtlich Methodik und Evidenzaufarbeitung. Die \u00dcbersicht fokussiert daher auf klinisch relevante Neuerungen und praktische Empfehlungen. Unabh\u00e4ngig von der jeweiligen Entwicklungsstufe bleibt die individuelle Anpassung jeder Leitlinienempfehlung an die konkrete Patient*innensituation essenziell.<\/jats:p>","DOI":"10.1007\/s00105-026-05795-y","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:10:53Z","timestamp":1791817853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle dermatologische Leitlinien in Deutschland: ausgew\u00e4hlte klinisch relevante Empfehlungen","Current dermatology guidelines in Germany: selected clinically relevant recommendations"],"prefix":"10.1007","author":[{"given":"Antonia","family":"Pennitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Berneburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Blume-Peytavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manig\u00e9","family":"Fartasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"G\u00f6rge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudula","family":"Kirtschig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph R.","family":"L\u00f6ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotraut","family":"M\u00f6\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cord","family":"Sunderk\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Niklas","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"5795_CR1","unstructured":"Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften (AWMF). AWMF-Regelwerk Leitlinien, Version 2.2 vom 22.05.2025 [Available from: https:\/\/www.awmf.org\/regelwerk\/] Zugegriffen: 13. Mai 2026."},{"key":"5795_CR2","unstructured":"S1-Leitlinie Diagnostik und Therapie Livedovaskulopathie. Version 2.1. 2025. Abrufbar unter: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/013-098. Zugegriffen: 13. Mai 2026."},{"key":"5795_CR3","unstructured":"S1-Leitlinie Empfehlungen zur UV-Therapie und Photochemotherapie. Version 5.0. 2026. Abrufbar unter: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/013-029. Zugegriffen: 13. Mai 2026."},{"key":"5795_CR4","unstructured":"S1-Leitlinie Management des eingewachsenen Nagels (Unguis incarnatus, Onychocryptosis) und des Zangennagels (Unguis in turriculo, Pincer-nail). Version 1.0. 2025. Abrufbar unter: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/013-106. Zugegriffen: 13. Mai 2026."},{"key":"5795_CR5","unstructured":"S1-Leitlinie Station\u00e4re dermatologische Rehabilitation. Version: 4.1. 2025. Abrufbar unter: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/013-083. Zugegriffen: 13. Mai 2026."},{"key":"5795_CR6","unstructured":"S2k-Leitlinie Diagnostik und Therapie des Pemphigus vulgaris \/ foliaceus und des bull\u00f6sen Pemphigoids. Version 3.0. 2026. Abrufbar unter: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/013-071. Zugegriffen: 13. Mai 2026."},{"key":"5795_CR7","first-page":"2154","volume":"94","author":"RE Bloch","year":"1997","unstructured":"Bloch\u00a0RE, Lauterbach\u00a0K, Oesingmann\u00a0U et\u00a0al (1997) Bekanntmachungen: Beurteilungskriterien f\u00fcr Leitlinien in der medizinischen Versorgung Beschl\u00fcsse der Vorst\u00e4nde von Bundes\u00e4rztekammer und Kassen\u00e4rztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl International 94:2154\u20132155","journal-title":"Dtsch Arztebl International"},{"key":"5795_CR8","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1111\/ddg.70065","volume":"24","author":"U Blume-Peytavi","year":"2026","unstructured":"Blume-Peytavi\u00a0U, Constantinou\u00a0A, Tomova-Simitchieva\u00a0T et\u00a0al (2026) S3 guideline diagnostics and therapy of alopecia areata - Part 1: Diagnostics and epidemiology. J\u00a0Dtsch Dermatol Ges 24:e1000\u2013e1015","journal-title":"J Dtsch Dermatol Ges"},{"key":"5795_CR9","doi-asserted-by":"publisher","first-page":"e1155","DOI":"10.1111\/ddg.70130","volume":"24","author":"U Blume-Peytavi","year":"2026","unstructured":"Blume-Peytavi\u00a0U, Constantinou\u00a0A, Tomova-Simitchieva\u00a0T et\u00a0al (2026) S3 guideline diagnostics and therapy in alopecia areata - Part 2: Therapy, psychosocial and cosmetic support. J\u00a0Dtsch Dermatol Ges 24:e1155\u2013e1177","journal-title":"J Dtsch Dermatol Ges"},{"key":"5795_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/ddg.70005x","volume":"24","author":"G M","year":"2026","unstructured":"Gina\u00a0M, Fartasch\u00a0M, Bauer\u00a0A et\u00a0al (2026) S2k guideline occupational skin products: skin protection creams, skin cleansing and skin care products. J\u00a0Dtsch Dermatol Ges 24:700\u2013711","journal-title":"J Dtsch Dermatol Ges"},{"key":"5795_CR11","first-page":"566","volume":"24","author":"G Kirtschig","year":"2026","unstructured":"Kirtschig\u00a0G, Woelber\u00a0L, Gunthert\u00a0A et\u00a0al (2026) Evidence- and consensus-based guideline on lichen sclerosus. J\u00a0Dtsch Dermatol Ges 24:566\u2013584","journal-title":"J Dtsch Dermatol Ges"},{"key":"5795_CR12","unstructured":"Mayser P, Abeck D, Bosshard PP et\u00a0al. Consensus-based Guideline on tinea capitis. J\u00a0Dtsch Dermatol Ges n\/a"},{"key":"5795_CR13","doi-asserted-by":"crossref","unstructured":"Mossner R, Cramer N, Gerdes S et\u00a0al. (2026) S1 Guideline: Therapy of generalized pustular psoriasis. J\u00a0Dtsch Dermatol Ges n\/a","DOI":"10.1111\/ddg.70244x"},{"key":"5795_CR14","first-page":"122","volume":"24","author":"A Nast","year":"2026","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M et\u00a0al (2026) S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: Treatment recommendations and monitoring. J\u00a0Dtsch Dermatol Ges 24:122\u2013137","journal-title":"J Dtsch Dermatol Ges"},{"key":"5795_CR15","first-page":"270","volume":"24","author":"A Nast","year":"2026","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M et\u00a0al (2026) S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations. J\u00a0Dtsch Dermatol Ges 24:270\u2013282","journal-title":"J Dtsch Dermatol Ges"},{"key":"5795_CR16","first-page":"254","volume":"23","author":"RN Werner","year":"2025","unstructured":"Werner\u00a0RN, Vader\u00a0I, Abunijela\u00a0S et\u00a0al (2025) German evidence- and consensus-based guideline on the management of penile urethritis. J\u00a0Dtsch Dermatol Ges 23:254\u2013275","journal-title":"J Dtsch Dermatol Ges"},{"key":"5795_CR17","first-page":"832","volume":"24","author":"C Zeyen","year":"2026","unstructured":"Zeyen\u00a0C, Abeck\u00a0D, Becker\u00a0K et\u00a0al (2026) S1 Guideline on Infected Interdigital Intertrigo (also called Gram-Negative Toe Web Infection). J\u00a0Dtsch Dermatol Ges 24:832\u2013843","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05795-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05795-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05795-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:10:57Z","timestamp":1791817857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05795-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":17,"alternative-id":["5795"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05795-y","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Pennitz, M.\u00a0Berneburg, M.\u00a0Fartasch, T.\u00a0G\u00f6rge, G.\u00a0Kirtschig, C.R.\u00a0L\u00f6ser, P.\u00a0Mayser, C.\u00a0Sunderk\u00f6tter, R.N.\u00a0Werner und A.\u00a0Nast geben an, dass kein Interessenkonflikt besteht. U.\u00a0Blume-Peytavi: Beraterin und\/oder Gutachterin: Galderma, LEO Pharma, Almirall, Cassiopeia, Johnson & Johnson, Sanofi Regeneron, Lilly, Pfizer; Mitarbeit in einem wissenschaftlichen Beirat (Advisory Board): Sanofi Regeneron, Boots Healthcare; bezahlte Vortrags-\/ oder Schulungst\u00e4tigkeit: AbbVie; Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien: LEO Pharma, Novartis, Mayne Pharma, Bioskin, Proderm. P. Mayser: Bezahlte Autor*innen-\/oder Coautor*innenschaft: Almirall. R.\u00a0M\u00f6\u00dfner: Mitarbeit in einem wissenschaftlichen Beirat (Advisory Board) und\/oder bezahlte Vortrags-\/ oder Schulungst\u00e4tigkeit und\/oder Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien: AbbVie, Almirall, Biogen IDEC, Boehringer Ingelheim, Celgene, Janssen-Cilag, LEO Pharma, Eli Lilly, MoonLake Immunotherapeutics AG, MSD, Novartis, Pfizer und UCB. A.\u00a0Tsianakas: Vorsitzender der AreD (Arbeitsgemeinschaft Rehabilitation in der Dermatologie). M.\u00a0Worm: Beraterin und\/oder Gutachterin: Sanofi; Mitarbeit in einem Wissenschaftlichen Beirat (Advisory Board): Sanofi; bezahlte Vortrags-\/ oder Schulungst\u00e4tigkeit Sanofi, Biotest AG.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor*innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}